You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Sienna said that Unilabs, a commercial lab in Sweden, is evaluating its hTERT bladder cancer test for routine use.
The test measures a set of three host-response proteins to help distinguish between bacterial and viral infections and guide use of antibiotics.
The company already offers an antibody test, Anti-SARS-CoV-2 Rapid Test, that it is distributing for its Chinese joint venture partner Autobio Diagnostics.
The FDA has added an at-home self-collection template to its SARS-CoV-2 EUA guidance as more firms seek to develop sampling kits for use in homes.
The company said it has production capacity for more than 50 million tests per month and that its high-throughput analyzers can deliver up to 440 tests per hour.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
The DXRX marketplace, planned for launch in the fourth quarter of 2020, will provide a way for pharmaceutical companies, diagnostic firms, and laboratories to collaborate.
The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms
The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.